• Kazuha Nakamura, Toshiaki Isogai, Hiroyuki Ohbe, Mikio Nakajima, Hiroki Matsui, Kiyohide Fushimi, and Hideo Yasunaga.
• Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan; Division of Emergency and Transport Services, National Center for Child Health and Development, Tokyo, Japan. Electronic address: kazuha.nakamura.m@gmail.com.
• Burns. 2024 Aug 4.

AbstractThe present study aimed to evaluate the effect of albumin administration on mortality in patients with severe burns. We retrospectively analyzed data from the Diagnosis Procedure Combination Database, a nationwide inpatient database in Japan. We identified patients in the database aged ≥ 15 years who were admitted with severe burns (burn index ≥15) from April 2014 to March 2021. We included patients who received albumin within 2 days of admission in the albumin group and those who did not in the control group. The outcome was the 28-day mortality. Eligible patients (n = 2492) were categorized into an albumin group (n = 1128) or a control group (n = 1364). One-to-one propensity score matching generated 530 pairs of patients with and without albumin administration. The 28-day mortality did not differ significantly between the two groups (albumin vs. control, 21.7 % vs. 22.8 %; risk difference, -1.1 %; 95 % confidence interval, -6.1 % to +3.9 %). These results suggest that albumin administration within 2 days of admission in patients with severe burns may not be associated with mortality during the acute phase.Copyright © 2024 Elsevier Ltd and International Society of Burns Injuries. All rights reserved.

5 keywords...

hide…